{"schema_version":"secwatch.filing_event.v1","accession":"0001798749-23-000053","form_type":"8-K","ticker":"JBIO","cik":"0001798749","company_name":"Jade Biosciences, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.283538+00:00","generated_at":"2026-06-11T12:16:02.848594+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aerovate Q2 net loss $19.0M; cash $150.1M; ATM raised $45M; Phase 2b/3 PAH trial on track","bullets":["Net loss of $19.0M for Q2 2023 vs $12.0M in Q2 2022; includes $3.0M stock comp.","Cash, cash equivalents and available-for-sale securities total $150.1M; runway extended into 2026.","Sold $45M common stock under ATM program; proceeds fund operations.","IMPAHCT Phase 2b/Phase 3 trial for AV-101 in PAH has >110 sites active in >20 countries; topline data expected Q2 2024.","Appointed Habib Dable (ex-Acceleron CEO) to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001798749-23-000053","json":"https://secwatch.observer/filing/0001798749-23-000053.json","markdown":"https://secwatch.observer/filing/0001798749-23-000053.md","text":"https://secwatch.observer/filing/0001798749-23-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000053/0001798749-23-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000053/tmb-20230814x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:16:02.848594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60c65baec02acb4ca0625710b26534a8ab167a43","claim":"Jade Biosciences, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended June 30, 2023, and recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1798749/000179874923000053/0001798749-23-000053-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}